SAN DIEGO, May 5, 2014 /PRNewswire/ -- Lpath, Inc. (LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the National Institutes of Neurological Diseases and Stroke (NINDS) that it has been awarded a $1.7 million, 2.5-year grant to develop its antibody therapeutic, Lpathomab™, which is directed against the bioactive lipid lysophosphatidic acid (LPA) for the treatment of traumatic brain injury (TBI).
The Phase l amount of $224,000 will fund studies designed to repeat in rats the efficacy previously demonstrated (several times in mice) in a controlled-cortical-impact model of TBI. Contingent on Phase I success, Phase II funds of almost $1.5 million will be used to advance Lpathomab through safety, pharmacology, and toxicology studies needed to file an IND.
My question is, why is this a 2.5 year grant when they are already planning to have a IND in early 2015?
DOD is supposed to be testing mice in a blast injury model now, then sheep, then monkeys.
If they replicate the mouse studies in a the cortical impact model for the NIH, do they then have to do more work with the 1.5 million, separate from the DOD work? Good time for a CC.
Haven't posted much in a long time simply because there is no reason to. It's good to see SOMETHING happening with Lpathomab™, but it seems strange that they are doing another phase 1 with rats, when they already had data with mice. I did not know that they could go from rats in a phase I to a phase II in humans either.
I've also never seen a company work so slowly when it comes to clinical trials.
Probably because rat is a better animal model for human TBI than mice. Or at least, if results confirm in rats, then it would look better for the IND. And of course, possible corporate partner.
HEY AREN'T GOING TO A PHASE 2 IN HUMANS, They are saying phase 2 of the grant (the majority of the money) is to get ready for a IND. Phase 1 of the grant is to replicate the previous mouse study.
I'm surprised they need to redo the mouse studies also, but at least it should go quickly.
DOD is supposed to go from mice, to sheep, to monkeys all in this year, and they just started recently.
True Slum. At least things are starting to percolate a little bit. Probably end of the year before any substantial price move...but it feels like its finally starting to steer in the right direction.
should relieve "some" concerns of dillution. Short-term - near triple bottom $4.05ish support. Good buy point for bounce back near $5.00. Although, weak market may stall any immediate upward move and allow opportunity to buy some cheap.